Halozyme Therapeutics FY Conference Summary Company Overview - **Company**: Halozyme Therapeutics (NasdaqGS: HALO) - **Event**: FY Conference held on March 03, 2026 Key Industry Insights - **Subcutaneous Drug Delivery**: Halozyme is positioned as a leader in subcutaneous (sub-Q) drug delivery, with a focus on expanding its platform and solutions for pharmaceutical and biotech companies [3][4] - **Market Trends**: There is a significant shift from intravenous (IV) infusion therapies to sub-Q treatments, driven by patient convenience and the desire for at-home administration [5] Core Company Developments - **New Deals and Acquisitions**: - Signed 3 new ENHANZE deals across oncology, inflammatory bowel disease, and obesity [3] - Acquired Elektrofi and Surf Bio for their hyperconcentration technologies, which allow biologics to be concentrated from 100 mg/mL to 500 mg/mL, reducing injection volume significantly [4] - **Future Growth**: The company anticipates durable revenue growth, particularly from HyperCon technologies, with intellectual property lasting into the mid-2040s [5] Financial Guidance and Royalties - **Patent Status**: - EU patent extended through 2029, maintaining mid-single-digit royalty rates for Darzalex [6] - U.S. patent extension is not currently assumed in long-term guidance, but a positive outcome could provide upside [9] - **Royalty Revenue Projections**: - Expected to generate $1 billion in royalty revenue by 2035 from 5-7 products, including new HyperCon assets [14] Product Launch Dynamics - **VYVGART Hytrulo**: - Total revenues of $4.2 billion, with strong uptake in sub-Q formulations, particularly in myasthenia gravis and CIDP indications [27][29] - Anticipated to double in sales, driven by the convenience of sub-Q administration [30] - **Ocrevus and Opdivo**: - Ocrevus sub-Q expected to expand the market by $2 billion, with strong adoption rates [35] - Opdivo aims to convert 30%-40% of its market to sub-Q, supported by recent J-code adoption [38] Regulatory Environment - **CMS and IRA Impact**: - Limited exposure to Medicare, with only 20% of sales affected by the IRA, suggesting minimal impact on future revenue [43] - Ongoing discussions regarding the classification of fixed combinations and their implications for patent protections [40] M&A Strategy - **Future Acquisitions**: - Halozyme remains open to additional M&A opportunities that align with its high-margin royalty business model, particularly in drug delivery [19][20] - **Focus on Current Platforms**: - The primary focus for the year is maximizing the value of existing platforms while exploring new partnerships [18] Conclusion - Halozyme Therapeutics is strategically positioned for growth in the subcutaneous drug delivery market, with a robust pipeline of products and technologies. The company is focused on expanding its partnerships, enhancing its revenue streams, and navigating regulatory challenges effectively.